Takeda Pharmaceutical and Seattle-based cell therapy startup Immusoft will collaborate to develop treatments in rare inherited metabolic disorders in a deal that could exceed $900 million.
Together, the partners will discover, develop and commercialize transformative cell therapies in rare inherited metabolic disorders with central nervous system (CNS) manifestations and complications using Immusoft’s Immune System Programming technology platform, which modifies a patient’s B cells and instructs the cells to deliver gene-encoded therapies. Ideally, the partnership gives Immusoft the resources it needs to further develop and validate its technology platform for the delivery of therapies in diseases for which patients have limited options.
The collaboration will focus on delivering protein therapeutics across the blood-brain barrier — a promising area of Immusoft’s research — which has the potential to enable the treatment of diseases with high unmet needs.
Under the terms of the deal, Immusoft will receive an undisclosed upfront payment and research funding support. The company is also eligible to receive future options and milestone payments with a total potential value of more than $900 million.
Read the press release